Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Atiq Rehman

Interventional Pain Medicine Morris, IL Medical Doctor

NPI 1457373730 CMS profile 66246

1802 N Division St Ste 605, Morris, IL 60450

Open in the dashboard

General payments

$1,947

77 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Atiq Rehman of Morris, IL is reported in the CMS Open Payments database as having received $1,947 across 77 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 35th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $338 8
2024 General $179 7
2023 General $348 16
2022 General $177 9
2021 General $227 7
2020 General $202 9
2019 General $475 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Atiq Rehman
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Atiq Rehman were reported at $338. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Atiq Rehman Interventional Pain Medicine median Middle half National median
2019 $475 $684 $216–$2,079 $163
2020 $202 $382 $122–$1,109 $114
2021 $227 $552 $167–$1,554 $132
2022 $177 $605 $187–$1,924 $149
2023 $348 $671 $195–$1,915 $160
2024 $179 $684 $206–$1,837 $164
2025 $338 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Nalu Medical, Inc. $275 13 payments
  2. Averitas Pharma Inc. $233 8 payments
  3. GRT US Holding, Inc. $196 9 payments
  4. Intuitive Surgical, Inc. $180 2 payments
  5. Abbott Laboratories $142 6 payments
  6. Allergan Inc. $126 6 payments
  7. Medtronic, Inc. $89 4 payments
  8. Avanos Medical $79 1 payment
  9. AstraZeneca Pharmaceuticals LP $77 1 payment
  10. Stratus Medical, LLC $76 3 payments
  11. Other $474 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,766 75 payments
  2. Travel and Lodging $180 2 payments
Products named General payments · program years 2019–2025
  1. Qutenza $429 17 payments
  2. Nalu Neurostimulation System $275 13 payments
  3. Da Vinci Surgical System $180 2 payments
  4. Proclaim Family of SCS IPGs $119 5 payments
  5. BOTOX $103 5 payments
  6. COOLIEF* COOLED RADIOFREQUENCY $79 1 payment
  7. BREZTRI $77 1 payment
  8. INTELLIS ADAPTIVESTIM $72 3 payments
  9. XTAMPZA $58 4 payments
  10. SPECTRA WAVEWRITER $51 1 payment
  11. Other $550 26 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

1,237

Median for Interventional Pain Management: 1,220

Drug cost

$36,893

Median for Interventional Pain Management: $39,344

Branded share of claims

44.2%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 411 $10,091
Nucynta Tapentadol Hcl Brand 13 $9,704
Hydromorphone Er Hydromorphone Hcl Brand 13 $3,681
Gabapentin Generic 237 $3,006
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 62 $2,188
Celecoxib Generic 70 $2,140
Cyclobenzaprine Hcl Generic 72 $1,443
Pregabalin Generic 56 $900
Butalbital-Acetaminophen-Caffe Butalb/Acetaminophen/Caffeine Brand 13 $805
Tizanidine Hcl Generic 61 $701

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 75 billing codes

Paid by Medicare

$398,218

Of which drugs: $23,528

Medicare patients

605

Average age 74

Services billed

24,644

384 women, 221 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 34%
Ischemic heart disease 32%
Depression 27%
Chronic kidney disease 26%
COPD 24%
Osteoporosis 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 378 1,227 $6,657
Injection, methylprednisolone acetate, 1 mg J1010 Office 119 12,300 $1,263
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 329 1,482 $430
Injection, midazolam hydrochloride, per 1 mg J2250 Office 179 1,553 $164
Injection, fentanyl citrate, 0.1 mg J3010 Office 141 195 $138
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 16 72 $57
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 26 201 $18
Injection, cefazolin sodium, 500 mg J0690 Office 14 15 $10

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qutenza
  • Averitas Pharma Inc. $104
$104 — —
UBRELVY
  • AbbVie, Inc. $15
$15 — —
BOTOX
  • AbbVie, Inc. $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

77 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record